Immunotherapy

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

By Eileen Koutnik-Fotopoulos

ASCO Annual Report, Immunotherapy

July 2017, Vol 7, No 7

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›

NCCN Updated Lung Cancer Guidelines Focus on Immunotherapy

July 2017, Vol 7, No 7

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

July 2017, Vol 7, No 7

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

By Phoebe Starr

June 2017, Vol 7, No 6

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

May 2017, Vol 7, No 5

Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab

May 2017, Vol 7, No 5

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

March 2017, Vol 7, No 3

Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer

By Walter Alexander

January 2017, Vol 7, No 1

Virtual Tumor Boards Expand Access to Clinical Trials and Immunotherapy in the Community Center Setting

By Meg Barbor, MPH

November 2016, Vol 6, No 11

Immunotherapy Takes Center Stage in the Updated NCCN Melanoma Guideline

By Wayne Kuznar

Immunotherapy, National Comprehensive Cancer Network (NCCN)

June 2016, Vol 6, No 6

Page 5 of 6

1
2
3
4
5
6